PepGen Inc. (PEPG)
Health Care · biotechnology · NASDAQ
PepGen is a clinical-stage biotechnology company developing peptide-enhanced oligonucleotide therapies to treat severe neuromuscular diseases, with a primary focus on Myotonic Dystrophy Type 1.
What PepGen Inc. does
PepGen is a clinical-stage biotechnology company focused on developing oligonucleotide therapies for severe neuromuscular and neurological diseases. Its proprietary Enhanced Delivery Oligonucleotide (EDO) platform utilizes cell-penetrating peptides to improve the delivery and efficacy of conjugated therapeutics. The company's lead product candidate, PGN-EDODM1, is currently in clinical development for the treatment of Myotonic Dystrophy Type 1 (DM1).
Recent developments
The FDA has placed a partial clinical hold on the FREEDOM2 trial in the U.S., while enrollment continues in other international regions. The DSMB recently recommended advancing the FREEDOM2 trial into its highest dose cohort (12.5 mg/kg) and approved dose escalation in the open-label extension study to 10 mg/kg, with data from the 10 mg/kg cohort expected in November 2026.
From PepGen Inc.'s filing of 2026-08-06.
Themes: neuromuscular diseases, oligonucleotide therapies, rare diseases / orphan drugs, genetic medicine
Fundamentals
- Price$2.72 as of 2026-10-21 close
- Market cap$188M as of 2026-08-02 (share count; price 2026-10-21)
- 1-year return-44.3% 2025-10-21 close $4.88 → 2026-10-21 close $2.72
- P/En/a negative earnings
- ROE-60.8% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Beta1.50 as of 2026-09-02
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How PEPG compares in its sector
- return on equitybottom 25% 510 covered Health Care peers, as of 2026-09-02
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | -$19M | -$18M | -$0.26 | -$16M† | $30000† |
| Q1 FY2026 2026-03-31 | -$19M | -$18M | -$0.26 | -$18M | $0 |
| Q4 FY2025 2025-12-31 | -$20M† | -$18M† | $0.02† | -$16M† | -$1000† |
| Q3 FY2025 2025-09-30 | -$19M | -$18M | -$0.52 | -$19M† | $97000† |
| Q2 FY2025 2025-06-30 | -$24M | -$23M | -$0.70 | -$24M† | $43000† |
| Q1 FY2025 2025-03-31 | -$31M | -$30M | -$0.92 | -$23M | $125000 |
| Q4 FY2024 2024-12-31 | -$24M† | -$22M† | -$0.68† | -$19M† | $228000† |
| Q3 FY2024 2024-09-30 | -$23M | -$21M | -$0.66 | -$24M† | $185000† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$23M
- Short-term investments$94M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How PepGen Inc. looks technically
PepGen Inc. (PEPG) is trading 17.3% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 117 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 19, below the 25 that marks a real trend), though buyers have been pushing harder than sellers lately — pressure, not a trend. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 53, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 7 trading days ago (its momentum flipped positive). It made a new 20-day low about 15 trading days ago. It is 65.1% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 17.3% below its 200-day average, the long-term trend line — a long-term downtrend | -17.4% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $2.82 | $2.82 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $3.29 | $3.29 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 20 calendar days ago — the swings before that are what the structure reading is measured on | 20 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 2.21. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 117 trading days ago — a "death cross", a bearish long-term signal | 117 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 19, below the 25 that marks a real trend), though buyers have been pushing harder than sellers lately — pressure, not a trend | 18.9 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 53, neither overbought (above 70) nor oversold (below 30) | 53.5 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($2.23 to $2.99) — its "stochastic" reading is 65 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 64.7 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 7 trading days ago (its momentum flipped positive) | 7 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $7.80 | $7.80 |
|---|---|---|
| From the 52-week high | it is 65.1% below its 52-week high (its highest price of the past year) | -65.1% |
| Above the 52-week low | it is 106.1% above its 52-week low (its lowest price of the past year) | +106.1% |
| Below the 52-week high | it is 65.1% below its highest point of the past year | 65.1% |
| Since a 20-day breakout | it made a new 20-day low about 15 trading days ago | 15 sessions |
| Since a 55-day breakout | it made a new 55-day high about 41 trading days ago | 41 sessions |
| All-time high | its highest closing price on record is $20.00 (set on 2023-03-24) | $20.00 |
| Given back of the 52-week move | over the past year its closes ranged ($1.35 to $7.17), and it has recovered roughly a quarter of its fall from last year’s high — 24% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $4.95 to $5.13. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 23.5% |
| From the all-time high | it is 86.4% below its all-time high | -86.4% |
| Nearest price level | it is trading 38.2% above a support level at $1.68 — a price it turned at twice since 2025-05-19, most recently on 2026-07-30. Since 2024-10-21 it has 4 such levels below the current price and 5 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -38.2% |
| All-time low | its lowest closing price on record is $0.88 (set on 2025-04-09) | $0.88 |
| Above the all-time low | it is 209.1% above its all-time low | +209.1% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 71% of it) | 29th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.2116 between its high and its low — about 7.8% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.2116 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $2.16 and $2.83 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $2.16 – $2.50 – $2.83 |
| Typical daily range (% of price) | its price moves about 7.8% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 7.8% |
| Stretch from the 200-day average | it is trading 2.7 daily ranges below its 200-day average price (17.4% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.7 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.30× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 9 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 9 sessions ago |
|---|---|---|
| Since a bullish engulfing | 4 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 4 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-21 0.7% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.7% |
|---|---|---|
| Open gap | it gapped 6.1% above the previous close 53 sessions ago and has not traded back through the level it left behind at 1.98 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +6.1% |
| Gap filled | a 2.4% gap down opened on 2026-10-14 has been "filled" 4 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 4 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 4.2 percentage points (the stock lost 4.2% while the market lost 0.1%) | -4.2% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 25.0 percentage points (the stock gained 28.3% while the market gained 3.3%) | +25.0% |
| vs market, 6 months | over the past 6 months this stock beat the market by 59.1 percentage points (the stock gained 68.9% while the market gained 9.8%) | +59.1% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 59.4 percentage points (the stock lost 44.3% while the market gained 15.2%) | -59.4% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: MACD momentum is positive, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-15 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 19.7% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 6% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $2.89 — a volume-weighted average of daily closes over 197 sessions, not a true tick-by-tick VWAP. | -5.8% |
|---|---|---|
| Vs the average paid since it last reported | the price is 2% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $2.77 — a volume-weighted average of daily closes over 54 sessions, not a true tick-by-tick VWAP. | -1.8% |
Price levels it has turned at before
PEPG last closed at $2.72 on 2026-10-21. Since 2024-10-21 it has turned at 4 prices below its last close and 5 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $1.68 | Support | 38.2% below the last close | turned there twice · 2025-05-19 to 2026-07-30 |
| $1.61 | Support | 40.6% below the last close | turned there twice · 2025-06-09 to 2026-06-26 |
| $1.35 | Support | 50.2% below the last close | turned there twice · 2025-06-03 to 2025-08-25 |
| $4.36 | Resistance | 60.3% above the last close | turned there twice · 2025-10-14 to 2025-10-22 |
| $4.49 | Resistance | 64.9% above the last close | turned there three times · 2024-12-27 to 2026-03-20 |
| $5.04 | Resistance | 85.4% above the last close | turned there three times · 2025-12-08 to 2026-03-05 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $2.21.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $4.10 and $5.27 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $2.21.
This reading has stood for 10 trading days, since 2026-10-08.
Read from daily closes as of 2026-10-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading below the 50-day moving average · Pulled back from the 12-month high · trendless / choppy (low ADX) · beating the market · Most volatile (6%+ typical daily range) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.38 mean, 1=Strong Buy…5=Strong Sell) — 8 analysts
- Mean price target$10.19 range $2.50 – $20.00; median $10.50
Analyst estimates, as of 2026-10-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for PEPG
- Consensus EPS estimate-$0.2733 next reporting period, as of 2026-10-18
- Estimate change, 30 days-$0.00666 from -$0.2667, on 2026-09-13, 35-day window
- Readings revised upward0% of 7 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Substantial dependence on the success of lead candidate PGN-EDODM1.","The company has no approved products, has never generated revenue, and remains unprofitable, with no assurance of future profitability.","The FREEDOM2 clinical study is subject to a partial clinical hold by the FDA in the United States."]
What changed in the latest 10-Q
AI-assisted comparison of PEPG's 10-Q filed 2026-05-12 against the prior one filed 2025-11-12.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-12) adds description of FREEDOM-OLE as an open label extension study for eligible participants who completed FREEDOM or FREEDOM2 studies
- Newer filing (2026-05-12) adds that FREEDOM study data was announced in 2025 with specific splicing correction percentages (12.3%, 29.1%, 53.7%)
- Newer filing (2026-05-12) adds that FREEDOM2 has received regulatory clearance in Canada, U.K., South Korea, Australia, and New Zealand
- Newer filing (2026-05-12) adds that FREEDOM2 remains on partial clinical hold in the U.S. and FDA questions are being addressed
- Newer filing (2026-05-12) adds topline results from FREEDOM2 5 mg/kg cohort with specific safety data (no SAEs, all related TEAEs mild, no cumulative toxicity)
- Newer filing (2026-05-12) adds discussion of outlier patient in FREEDOM2 affecting splicing correction mean (7.3% overall vs. 22.9% excluding outlier)
- Newer filing (2026-05-12) adds information on middle finger vHOT showing positive trend in treatment group versus worsening in placebo group
- Newer filing (2026-05-12) adds that FREEDOM2 is currently dosing 10 mg/kg cohort with data expected in second half of 2026
- Newer filing (2026-05-12) adds that EMA granted orphan medicinal product designation to PGN-EDODM1
- Newer filing (2026-05-12) adds that during three months ended March 31, 2026, 237,500 shares were sold under ATM program for net proceeds of $1.5 million
- Removed:
- Older filing (2025-11-12) includes 'Business Update' section header which is removed in newer filing
- Older filing (2025-11-12) states clinical development program includes two studies; newer filing (2026-05-12) states three studies (adds FREEDOM-OLE)
- Older filing (2025-11-12) states FREEDOM study is currently enrolling; newer filing (2026-05-12) states data was announced in 2025
- Older filing (2025-11-12) states FREEDOM2 is 'currently open' in Canada and U.K.; newer filing (2026-05-12) states it 'has received regulatory clearance' in multiple jurisdictions and is 'currently enrolling'
- Older filing (2025-11-12) states FREEDOM2 'plan[s] to open' in U.S. subject to regulatory authorization; newer filing (2026-05-12) states it 'remains on partial clinical hold in the U.S.'
- Older filing (2025-11-12) states all 5 mg/kg cohort participants have been enrolled with data expected in Q1 2026; newer filing (2026-05-12) reports topline results from 5 mg/kg cohort already released
- Older filing (2025-11-12) includes paragraph describing discontinuation of PGN-EDO51 development and winding down of DMD-related activities; this is completely removed in newer filing
- Older filing (2025-11-12) uses phrase 'shares of common stock shares' (with duplication); newer filing (2026-05-12) corrects to 'shares of common stock'
- Older filing (2025-11-12) states estimated offering expenses; newer filing (2026-05-12) states offering expenses without 'estimated'
- Reworded:
- Older filing (2025-11-12) states 'In the FREEDOM study, we are enrolling'; newer filing (2026-05-12) states 'In the FREEDOM study, we enrolled' (change from present to past tense)
- Older filing (2025-11-12) reports data announcement on February 24 and September 24, 2025; newer filing (2026-05-12) consolidates as 'announced data...in 2025'
- Older filing (2025-11-12) states 'we have decided to conclude dose escalation'; newer filing (2026-05-12) removes this statement and instead discusses ongoing dosing of 10 mg/kg cohort
- Notes:
- The newer filing text appears truncated at the end ('establishing and mai'), potentially affecting completeness of comparison in final paragraph
- Some changes reflect reporting of completed events (FREEDOM study results) versus ongoing enrollment status in older filing
Risk Factors
- Added:
- Added new risk factor 'We are substantially dependent on the success of our lead product candidate, PGN-EDODM1' as the first substantive risk factor in the 2026-05-12 filing
- Added specific language about 'partial clinical hold placed on the FREEDOM2 study' and need for 'successful outcome of discussions with the U.S. Food and Drug Administration' in 2026-05-12 filing
- Added reference to obtaining 'clearance to initiate sites in additional jurisdictions (such as the US)' as potential delay factor in 2026-05-12 filing
- Added phrase 'or other CMC activities which support registration, particularly as we scale for an anticipate Phase 3 pivotal trial and look to secure secondary source suppliers for our drug substance' in 2026-05-12 filing
- Removed:
- Removed 'manufacturing' from the list of resource allocation activities in the older filing; newer filing specifies this separately
- Removed statement 'We are still in the early stages of development of our programs and have only advanced two product candidates into clinical development' from 2025-11-12 filing
- Removed statement 'We announced in May 2025 that we are focusing our efforts on the development of PGN-EDODM1 and have voluntarily discontinued development of PGN-EDO51' from 2025-11-12 filing
- Removed bullet point about 'obtain, expand, maintain, defend and enforce our intellectual property portfolio' as separate item from 2025-11-12 filing
- Removed bullet point 'hire additional clinical, regulatory and scientific personnel' from 2025-11-12 filing
- Removed bullet point 'ultimately establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval' from 2025-11-12 filing
- Removed bullet point 'add operational, legal, compliance, financial and management information systems and personnel to support our research, product development and future commercialization efforts, as well as to support our operations as a public company' from 2025-11-12 filing
- Removed entire separate risk factor 'We have never generated revenue from product sales and may never achieve or maintain profitability' that appeared in 2025-11-12 filing
- Reworded:
- Changed financial metrics from 'nine months ended September 30, 2025 and September 30, 2024' with net losses of '$71.3 million and $67.7 million' and accumulated deficit of '$342.8 million' in older filing to 'three months ended March 31, 2026 and March 31, 2025' with net losses of '$17.8 million and $30.2 million' and accumulated deficit of '$378.9 million' in newer filing
- Changed description from 'currently only have one product candidate advancing into clinical development' (older) to removed statement about number of candidates (newer)
- Expanded bullet point on manufacturing from 'establish manufacturing sources for your product candidates and secure supply chain capacity to provide sufficient quantities for preclinical and clinical development and commercial supply' (2025-11-12) to include 'and other CMC activities which support registration, particularly as we scale for an anticipate Phase 3 pivotal trial and look to secure secondary source suppliers for our drug substance' (2026-05-12)
- Modified enrollment concern from 'including if enrollment for the FREEDOM2 study takes longer than anticipated' (2025-11-12) to 'including if enrollment for the FREEDOM2 study takes longer than anticipated or if we are unable to obtain clearance to initiate sites in additional jurisdictions (such as the US)' (2026-05-12)
- Added new bullet point 'address any new safety or efficacy concerns which may arise as we analyze interim, top-line, or preliminary data from the ongoing FREEDOM2 clinical trial, or other planned or future clinical trials' in 2026-05-12 filing
- Notes:
- The newer filing appears to be truncated mid-sentence ('seek marketing approvals for any') and may not contain the complete risk factors section
- Comparison is between a 10-Q for period ended March 31, 2026 (newer) and a 10-Q for period ended September 30, 2025 (older), representing different reporting periods which may naturally account for some content changes
- The older filing's section appears similarly truncated at the end, making complete structural comparison impossible for later portions
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 6 days since 2026-10-16 have not been checked yet.
- Last 180 days · read to 2026-10-160 buys · 1 sell ($1739) — 1 selling insider
Most recent open-market transaction: 2026-05-21. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about PEPG's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
6 institutional 13F filers reported holding PEPG as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 7,880,958
- Reported value $14,185,725
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 3 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about PEPG's institutional holders → See what each manager we track holds →
Short interest (FINRA)
PEPG had 4,225,473 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
PEPG had 6.10% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.77 days to cover at the same settlement.
- Reported short interest (shares) 4,225,473
- Short interest (% of shares outstanding) 6.10%
- Prior settlement (shares) 3,871,203
- Reported change 9.15%
- Days to cover (reported) 4.77
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Wave Life Sciences (WVE)
- Avidity Biosciences (RNA)
- Dyne Therapeutics (DYN)
- Sarepta Therapeutics (SRPT)
- Ionis Pharmaceuticals (IONS)
- Biogen (BIIB)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare PEPG vs…
PepGen Inc. is found in…
PEPG ranks in…
Frequently asked questions
What does PepGen Inc. (PEPG) do?
PepGen is a clinical-stage biotechnology company focused on developing oligonucleotide therapies for severe neuromuscular and neurological diseases. Its proprietary Enhanced Delivery Oligonucleotide (EDO) platform utilizes cell-penetrating peptides to improve the delivery and efficacy of conjugated therapeutics. The company's lead product candidate, PGN-EDODM1, is currently in clinical development for the treatment of Myotonic Dystrophy Type 1 (DM1).
What sector is PepGen Inc. (PEPG) in?
PepGen Inc. (PEPG) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are PepGen Inc.'s (PEPG) competitors?
Notable peers of PepGen Inc. (PEPG) include Wave Life Sciences, Avidity Biosciences, Dyne Therapeutics, Sarepta Therapeutics and Ionis Pharmaceuticals. This peer set is informational only — not financial advice.
Is PepGen Inc. (PEPG) overbought or oversold right now?
PepGen Inc. (PEPG) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 53, in the neutral middle (as of 2026-10-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on PEPG come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.